Abstract
Since the discovery of phenothiazines as tau protein aggregation inhibitors, many additional small molecule inhibitors of diverse chemotype have been discovered and characterized in biological model systems. Although direct inhibition of tau aggregation has shown promise as a potential treatment strategy for depressing neurofibrillary lesion formation in Alzheimer’s disease, the mechanism of action of these compounds has been unclear. However, recent studies have found that tau aggregation antagonists exert their effects through both covalent and non-covalent means, and have identified associated potency and selectivity driving features. Here we review small-molecule tau aggregation inhibitors with a focus on compound structure and inhibitory mechanism. The elucidation of inhibitory mechanism has implications for maximizing on-target efficacy while minimizing off-target side effects.
Keywords: Alzheimer’s disease, aggregation, neurofibrillary tangle, paired helical filaments, tau.
Current Alzheimer Research
Title:Structure and Mechanism of Action of Tau Aggregation Inhibitors
Volume: 11 Issue: 10
Author(s): Katryna Cisek, Grace L. Cooper, Carol J. Huseby and Jeff Kuret
Affiliation:
Keywords: Alzheimer’s disease, aggregation, neurofibrillary tangle, paired helical filaments, tau.
Abstract: Since the discovery of phenothiazines as tau protein aggregation inhibitors, many additional small molecule inhibitors of diverse chemotype have been discovered and characterized in biological model systems. Although direct inhibition of tau aggregation has shown promise as a potential treatment strategy for depressing neurofibrillary lesion formation in Alzheimer’s disease, the mechanism of action of these compounds has been unclear. However, recent studies have found that tau aggregation antagonists exert their effects through both covalent and non-covalent means, and have identified associated potency and selectivity driving features. Here we review small-molecule tau aggregation inhibitors with a focus on compound structure and inhibitory mechanism. The elucidation of inhibitory mechanism has implications for maximizing on-target efficacy while minimizing off-target side effects.
Export Options
About this article
Cite this article as:
Cisek Katryna, Cooper L. Grace, Huseby J. Carol and Kuret Jeff, Structure and Mechanism of Action of Tau Aggregation Inhibitors, Current Alzheimer Research 2014; 11 (10) . https://dx.doi.org/10.2174/1567205011666141107150331
DOI https://dx.doi.org/10.2174/1567205011666141107150331 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of the Anti-Amyloidogenic Secretase ADAM10 in Shedding the APP-like Proteins
Current Alzheimer Research Preface [Hot Topic: Multifunctional Drug Targets (Executive Editors: H.E. Tibbles and A.O. Vassilev)]
Current Pharmaceutical Design Prospects for Rational Development of Pharmacological Gap Junction Channel Blockers
Current Drug Targets Oxazolidinones as Chiral Auxiliaries in the Asymmetric 1,4-Conjugate Addition Reaction Applied to the Total Synthesis of Natural Products: A Supplemental Mini-Review
Current Organic Synthesis Homocysteine in Neurological Disease: A Marker or a Cause?
CNS & Neurological Disorders - Drug Targets Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery
Current Topics in Medicinal Chemistry Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Inhibition of Brain Ischemia-Caused Notch Activation in Microglia May Contribute to Isoflurane Postconditioning-Induced Neuroprotection in Male Rats
CNS & Neurological Disorders - Drug Targets Novel Histone Deacetylase Inhibitors for the Treatment of Pediatric Brain Tumors
Central Nervous System Agents in Medicinal Chemistry The Influence of Cox-2 and Bioactive Lipids on Hematological Cancers
Current Angiogenesis (Discontinued) Nitric Oxide and Dietary Factors: Part V Summary/Conclusion and References
Vascular Disease Prevention (Discontinued) Immunotherapy of Cancer Based on DC-Tumor Fusion Vaccine
Current Immunology Reviews (Discontinued) <i>In Vitro</i> Cytotoxicity and Apoptosis Inducing Evaluation of Novel Halogenated Isatin Derivatives
Anti-Cancer Agents in Medicinal Chemistry Differential Susceptibility of Naive and Differentiated PC-12 Cells to Methylglyoxal-Induced Apoptosis: Influence of Cellular Redox
Current Neurovascular Research Human Platelets Express Authentic CB1 and CB2 Receptors
Current Neurovascular Research Withania somnifera Phytochemicals Confer Neuroprotection by Inhibition of the Catalytic Domain of Human Matrix Metalloproteinase-9
Letters in Drug Design & Discovery Iron Chelators as Anti-Neoplastic Agents: Current Developments and Promise of the PIH Class of Chelators
Current Medicinal Chemistry Membrane Localization of Estrogen Receptors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Patent Selections
Recent Patents on DNA & Gene Sequences The ‘Other’ Telomerase Inhibitors: Non-G-Quadruplex Interactive Agent, Non-Antisense, Non-Reverse Transcriptase Telomerase Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents